Abeona Therapeutics Q4 Earnings Call Highlights

Abeona Therapeutics (NASDAQ:ABEO) executives said the institution is seeing increasing diligent request for ZEVASKYN, an autologous cell-based cistron therapy approved successful April 2025 for adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), portion outlining aboriginal commercialized traction, reimbursement progress, manufacturing capableness plans, and full-year 2025 fiscal results.

Chief Executive Officer Dr. Vish Seshadri said ZEVASKYN’s commercialized motorboat was delayed until the 4th fourth of 2025 arsenic the institution optimized a sterility trial required for merchandise release. Abeona treated its archetypal commercialized diligent successful December 2025, a milestone Seshadri described arsenic the commencement of broader motorboat execution successful 2026, with a absorption connected establishing a accordant cadence of biopsies, manufacturing, merchandise delivery, and treatments.

→ Home Depot Stock Keeps Falling—Analysts Say the Upside Is Still There

Since resuming manufacturing successful precocious January pursuing an yearly shutdown, Seshadri said Abeona has treated 1 diligent during the existent quarter, biopsied 3 further patients with treatments scheduled successful coming weeks, and expects to execute further biopsies during the month. Chief Commercial Officer Dr. Madhav Vasanthavada added that since the Q4 2025 launch, 2 patients person been treated, 3 much person been biopsied for attraction successful the coming weeks, and astatine slightest 10 further patients are advancing done administrative steps with second-quarter 2026 biopsies targeted.

All diligent treatments and biopsies to day person travel from the archetypal 2 of 4 qualified attraction centers (QTCs): Lurie Children’s Hospital successful Chicago and Lucile Packard Children’s Hospital astatine Stanford. Seshadri said the remaining 2 activated QTCs—Children’s Hospital of Colorado and the University of Texas Medical Branch (UTMB) successful Galveston—are opening to docket patients into upcoming biopsy slots.

→ Data Storage to Data Intelligence: Everpure's Big AI Era Rebrand

Vasanthavada emphasized that onboarding caller QTCs is simply a multi-step process that tin instrumentality respective months, requiring organization approvals and the constitution of operational components including a maestro work agreement, commercialized policy, objective training, and registry protocols with IRB approvals. He said 2 QTCs person started treating patients and the different 2 person patients moving done the administrative process to docket biopsies.

In summation to the 4 activated QTCs, absorption said it is actively moving toward onboarding 5 further centers successful assorted stages, with a extremity of having astatine slightest 7 QTCs progressive by the extremity of 2026. On the Q&A information of the call, Vasanthavada said 1 further halfway is “imminent” and the institution hopes to denote it successful the coming quarter. Management besides indicated that, owed to the magnitude of the onboarding process, immoderate imaginable sites could spill into adjacent twelvemonth adjacent arsenic the institution targets 7 activated sites wrong the year.